-
Harbin Gloria Partners with Genolmmune on PD-1 and Neoantigen Therapy for NSCLC
•
China-based Harbin Gloria Pharmaceuticals Co., Ltd (SHE: 002437) has partnered with Genolmmune Therapeutics Biotechnology Co., Ltd, a BGI Genomics subsidiary focused on tumor immune cell therapy. The collaboration aims to develop Gloria’s PD-1 monoclonal antibody zimberelimab in combination with Genolmmune’s injectable Neo-T neoantigen immunotherapy for non-small cell lung cancer (NSCLC).…
